R
Richard J. Colonno
Researcher at Bristol-Myers Squibb
Publications - 146
Citations - 14924
Richard J. Colonno is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Entecavir & Hepatitis B virus. The author has an hindex of 57, co-authored 141 publications receiving 14236 citations. Previous affiliations of Richard J. Colonno include Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity.
Ping Chen,Peter T. W. Cheng,M. Alam,B. D. Beyer,G. S. Bisacchi,Tamara Dejneka,A. J. Evans,Jill A. Greytok,Mark A. Hermsmeier,William G. Humphreys,G. A. Jacobs,O. Kocy,P.-F. Lin,K. A. Lis,M. A. Marella,Denis E. Ryono,Amy K. Sheaffer,S. H. Spergel,Chongqing Sun,Joseph A. Tino,Gregory D. Vite,Richard J. Colonno,Robert Zahler,Joel C. Barrish +23 more
TL;DR: It was found that appropriate substitution at the para position of the P1' phenyl group of 1 resulted in the identification of equipotent compounds (10l, 10m, 10n, and 15c) which possess significantly decreased cytotoxicity.
Journal ArticleDOI
pH-Dependent Changes in Photoaffinity Labeling Patterns of the H1 Influenza Virus Hemagglutinin by Using an Inhibitor of Viral Fusion
Christopher Cianci,Kuo Long Yu,Douglas D. Dischino,William E. Harte,Milind Deshpande,Guangxiang Luo,Richard J. Colonno,Nicholas A. Meanwell,Mark Krystal +8 more
TL;DR: Analysis of purified HA trimers suggested a model whereby the BHA is able to undergo a partial, reversible structural change in the presence of inhibitor compound, and identified a potential binding pocket within the HA2 N terminus which interacts with the photoaffinity compound.
Journal ArticleDOI
Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics
Zheng Yang,Lisa Zadjura,Celia D’Arienzo,Anthony M. Marino,Kenneth S. Santone,Lewis J. Klunk,Douglas S. Greene,Pin-Fang Lin,Richard J. Colonno,Tao Wang,Nicholas A. Meanwell,Steven Hansel +11 more
TL;DR: A mechanistic approach that factors in absorption and first‐pass metabolism was employed to predict the human oral bioavailability of BMS‐378806 and provide important guidance to improving absorption and half‐life of future compounds in the series.
Journal ArticleDOI
Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731.
Qi Huang,Dawei Cai,Ran Yan,Lichun Li,Yuhua Zong,Lida Guo,Alexandre Mercier,Yi Zhou,Ariel Tang,Kirk Henne,Richard J. Colonno +10 more
TL;DR: In addition to its potency and novel mechanism of action, ABI-H0731 possesses drug-like properties and a preclinical pharmacokinetic profile supportive of once-daily dosing in patients with CHB, and these data support the ongoing clinical development of A BI-H731 as a treatment for HBV.
Journal ArticleDOI
In vitro synthesis of messenger RNA by a defective interfering particle of vesicular stomatitis virus.
TL;DR: A defective interfering particle derived from the heat-resistant strain of vesicular stomatitis virus was analyzed for the presence of virion-associated RNA polymerase (nucleosidetriphosphate:RNA nucleotidyltransferase, EC 2.7.6) activtiy.